Oxford BioDynamics has completed its validation trial and demonstrated high accuracy for its EpiSwitch™ based test to differentiate Melanoma from Non-Melanoma skin cancers, Basal Cell Carcinoma and Squamous Cell Carcinoma.
Completion of clinical trial for the EpiSwitch™ technology, differentiating Melanoma from Non-Melanoma skin cancers, Basal Cell Carcinoma and Squamous Cell Carcinoma.
June 10, 2011
|In Milestones